Lead Plaintiff Deadline: February 06, 2023
Please Upload related files below
Fill in below.
Looking for more?
common stock between May 11, 2022, and November 9, 2022
1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company’s interactions with the United States Food and Drug Administration; 2) defendants misled Veru’s shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization (“EUA”) and even the submission of a New Drug Application without any further studies; and 3) the Company’s filings concealed the true risks faced by Veru in gaining approval for its EUA request.
In order to be included in the lawsuit, you must have incurred a loss on shares of Veru purchased or acquired during the class period listed above and/or pursuant to the stock offering(s) referenced above.
If you suffered a loss in Veru during the relevant time frame or pursuant to the relevant offering(s), you have until February 06, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.